Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2026-01-14 00:00:00 ET · period of report 2026-01-12 · accession 0001831216-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-01-14 | 2026-01-12 | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale+OE | $28.34 | -10.0K | 144.8K | -6% | -$283.4K |
| DM | 2026-01-14 | 2026-01-13+ | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | M - OptEx | $4.87 | +100.0K | 592.8K | +20% | +$487.0K |
| DM | 2026-01-14 | 2026-01-13+ | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | S - Sale+OE | $28.24 | -100.0K | 542.8K | -16% | -$2.82M |
| DM | 2026-01-14 | 2026-01-13+ | OLMA | Myles David C. | CH. DISCOV, NON-CLIN DEV OFF | M - OptEx | $0.00 | -100.0K | 100.0K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-12 | S | D | 10,000 | $28.34 | 144,846 | I See Footnote | — | — | (F1) The weighted average sale price for the transaction reported was $28.34, and the range of prices were between $28.07 and $28.66. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. (F2) The shares are held by Myles Properties Inc., of which the Reporting Person is President. |
| 2 | Common | Common Stock | 2026-01-13 | M | A | 50,000 | $4.87 | 592,761 | D | — | — | (F3) On December 23, 2025, the Reporting Person filed a Form 4 that contained a scrivener's error that resulted in the number of shares beneficially owned directly by the Reporting Person to be overstated by 120 shares. That error has been corrected in this Form 4. |
| 3 | Common | Common Stock | 2026-01-13 | S | D | 49,800 | $27.60 | 542,961 | D | — | — | (F4) The weighted average purchase price for the transaction reported was $27.60, and the range of prices were between $27.35 and $28.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. |
| 4 | Common | Common Stock | 2026-01-13 | S | D | 200 | $28.49 | 542,761 | D | — | — | |
| 5 | Common | Common Stock | 2026-01-14 | M | A | 50,000 | $4.87 | 592,761 | D | — | — | |
| 6 | Common | Common Stock | 2026-01-14 | S | D | 14,997 | $28.60 | 577,764 | D | — | — | (F5) The weighted average sale price for the transaction reported was $28.60, and the range of prices was between $27.80 and $28.79. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 7 | Common | Common Stock | 2026-01-14 | S | D | 35,003 | $28.99 | 542,761 | D | — | — | (F6) The weighted average sale price for the transaction reported was $28.99, and the range of prices was between $28.80 and $29.39. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 8 | Derivative | Stock Option (Right to Buy) | 2026-01-14 | M | D | 50,000 | $0.00 | 50,000 | D | $4.87 · — to 2033-01-31 | 50,000 Common Stock | (F9) 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-01-13 | M | D | 50,000 | $0.00 | 100,000 | D | $4.87 · — to 2033-01-31 | 50,000 Common Stock | (F8) 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |